Fig. 8.

Expression of VHL in prostate and liver. a VHL immunostaining in transverse sections of prostate ventral lobes from wild-type control (WT), EAF2^−/−, VHL^+/− and EAF2^−/−VHL^+/− mice at age 20–24 mos. VHL^+/− mice displayed sporadic negative VHL immunoreactivity (black arrows), and EAF2^−/−VHL^+/− mice displayed negative VHL immunoreactivity in PIN lesions (black arrow). b VHL immunostaining of in transverse sections of liver from wild-type control (WT), EAF2^−/−, VHL^+/− and EAF2^−/−VHL^+/− mice at age 20–24 mos. Proliferating oval cells near areas of angiectasis in VHL^+/− animals were negative (black arrow) and surrounding hepatocytes had reduced VHL immunoreactivity. EAF2^−/−VHL^+/− mice displayed areas of intense cytoplasmic staining of hepatocytes (black arrows) and negative VHL immunoreactivity in proliferating oval cells and hepatocytes (inset, dashed arrow) near areas of angiectasis